Shankar Balasubramanian: Indian-Origin Chemist In Millennium Tech Prize-Winning Team For Revolutionary DNA Sequencing Tech
by Bhaswati Guha Majumder - May 19, 2021 02:32 PM
Prize winners David Klenerman (L) and Shankar Balasubramanian (R)
Snapshot
The development of next-generation DNA sequencing technology earns Cambridge University chemists a prestigious global science and technology prize.
Part of the winning duo is a chemist of Indian origin.
Shankar Balasubramanian, a British-Indian chemist from the University of Cambridge, has been declared the winner of the 2020 Millennium Technology prize along with his colleague David Klenerman.
The duo was awarded the prestigious science and technology prize on 18 May by the President of the Republic of Finland, Sauli Niinisto, who is the Patron of the prize, during a virtual ceremony.
New report says Cambridge Biomedical Campus will double in size in next 20 years
The campus occupiers - including Cambridge University, AstraZeneca, and Addenbrooke s - have published a vision for its future.
The Cambridge Biomedical Campus. (Image: Cambridge University Health Partners)
Sign up to our newsletter for daily updates and breaking newsInvalid EmailSomething went wrong, please try again later.
Sign up here!
When you subscribe we will use the information you provide to send you these newsletters. Your information will be used in accordance with ourPrivacy Notice.
Thank you for subscribingWe have more newslettersShow meSee ourprivacy notice
The Cambridge Biomedical Campus (CBC) will nearly double in size in just 20 years as the city “strains at its borders”.
A light at the end of the tunnel : How charities paved the way out of the pandemic
Stephen Delahunty talks to charity researchers, staff and volunteers about the parts they have played in supporting the rollout of the Covid-19 vaccine
by Stephen Delahunty
Patients wait after receiving their Covid-19 jabs at a vaccination centre at Salisbury Cathedral. Photo: Dan Kitwood/Getty Images
Sign in to continue
Free email bulletins
NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NeoGenomics, Inc.: NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million
Completes $200 million strategic financing with leading oncology-focused specialist investors
FT. MYERS, FL / ACCESSWIRE / May 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has agreed to acquire Inivata Ltd, a global, commercial stage liquid biopsy platform company headquartered in Cambridge, England. The acquisition follows a $25 million minority equity investment by NeoGenomics in Inivata in May 2020, at which time NeoGenomics was granted a fixed price option to purchase the remainder of Inivata for $390 million prior to December 31, 2021. The cash purchase price will be funded with balance sheet cash and through